Last week, our regulatory experts Maria Castellà Castellà and Alejandro Ballester participated in the fourth consortium meeting of the #EUfunded GreenNanoBone project in #Barcelona, Spain.
Two key highlights from the meeting:
ASPHALION presented the Preclinical Development Plan, outlining the non-clinical studies needed to move the product toward its first Clinical Investigation.
The plan follows a risk-based approach built on the latest standards. It is designed as a living document that will evolve with the product and available data.
Turning regulatory strategy into a concrete development plan is a key step to ensure that scientific progress translates into a safe and effective solution for patients.
The EU-Funded GreenNanoBone project aims to develop sustainable 4D biomaterials from potato waste to prevent and treat medication-related osteonecrosis of the jaw (MRONJ)—a serious side effect of Bone Targeting Agents (BTAs) experienced by thousands of cancer survivors.
Need help with your EU-funded projects? Contact us at: [email protected]







